MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial
MSD’s TROP2-directed antibody-drug conjugate (ADC), sac-TMT, has shown benefit in both overall survival (OS) and progression-free survival (PFS) in a…
Oncology
-
-
New findings link common pesticide to early-onset colorectal cancer
The World Health Organization cites colorectal cancer (CRC) as the second leading cause of cancer-related deaths worldwide. Although it predominantly…
-
Pfizer hoping for earlier Elrexfio use in RRMM after Phase III trial
Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug showed…
-
Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC)…
-
Storm clinches $56m in Series C for Phase II on lead sarcoma drug
British cancer biotech Storm Therapeutics has secured $56m in a Series C financing round to push its sarcoma therapy, STC-15,…
-
PDS Biotech’s stock up on colorectal cancer trial success
PDS Biotech’s stock has jumped nearly 25% after its tumour-targeting fused antibody drug conjugate (ADC) elicited a 78% response in patients…
-
Lilly’s Jaypirca racks up fourth Phase III CLL win
Eli Lilly’s Jaypirca (pirtobrutinib) has succeeded in its fourth Phase III trial in chronic lymphocytic leukaemia (CLL). The Phase III…
-
Never-married individuals reported to have higher cancer risk
Cancer is the leading cause of death globally, accounting for one in six deaths worldwide in 2020, according to the…
-
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial
AbbVie’s Elahere has shown a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase…
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of…
